113 related articles for article (PubMed ID: 1714288)
1. Prostate-specific antigen: a valuable clinical tool.
Oesterling JE
Oncology (Williston Park); 1991 Apr; 5(4):107-22; discussion 122, 125-6, 128. PubMed ID: 1714288
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
3. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
Stamey TA
Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Kabalin JN
Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941
[TBL] [Abstract][Full Text] [Related]
7. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
Rodríguez Duarte C; Aguillón J; Rodríguez H
Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
Barak M; Mecz Y; Lurie A; Gruener N
J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
12. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V
Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
15. [Prostate-specific antigen as a prostatic tumor marker. Analysis of results in 206 patients].
Rodríguez Duarte C
Arch Esp Urol; 1991; 44(6):697-700. PubMed ID: 1722962
[TBL] [Abstract][Full Text] [Related]
16. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
17. [The role of PSA in prostatic adenocarcinoma].
Manca GP
Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
[TBL] [Abstract][Full Text] [Related]
18. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
19. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
20. [The clinical use of the prostate-specific antigen in patients with prostatic cancer].
Matveev BP; Sokolov AV; Bukharkin BV; Ledian KM; Tilk AE; Makarova GV
Urol Nefrol (Mosk); 1991; (4):8-12. PubMed ID: 1719686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
